Background: 6-Gingerol and 6-Shogaol are novel biologically active phenol compounds isolated from rhizomes of Ginger (Zingiber officinale Roscoe), which has a potential role as anti-inflammatory, anti-oxidant and apoptotic. Till date there are no scientific reports on the functional properties of Ginger against the molecular mechanisms of angiogenesis, lymphangiogenesis, and metastasis. Hence, in the present study we have explored the feasibility of active ginger compounds (6-Gingerol and 6-Shogaol) to validate their molecular mechanisms on angiogenesis and lymphangiogenesis in breast cancer progression through in silico approach.
Introduction
Cancer is a leading cause of death worldwide. According to the reports from the Indian Council of Medical Research, India is likely to have more than 17.3 lakh newly diagnosed cases and over 8.8 lakh deaths due to cancer by the year 2020 (http: //www.dailypioneer.com/nation/over-17-lakh-new-cancer-cases-in-india-by-2020-icmr.html) . Breast cancer is the most common cancer in India followed by lung and cervical cancer (Include reference). It is estimated that there were nearly 1.5 lakh new cases of breast cancer in 2016,which is more than 10% all new cancer cases in 2016 (https://timesofindia.indiatimes.com/india/Cancer-cases-in-India-likely-to-soar-25-by-2020-ICMR/articleshow/5233463 2.cms). The prevalence of primary as well as secondary breast cancer is also increasing alarmingly in Asia due the delay in diagnosis, unawareness as well as treatment failures. Neovascularisation, which is formation of new blood and lymphatic vessels, plays a key role in tumor development and progression (Nishida et al, 2006) . Several pathways play a vital role in angiogenesis and among these the vascular endothelial growth factor (VEGF) pathway has diverse activity in cell types like muscle (Bryan et al, 2008) , neuronal cells (Jin et al, 2006) and endothelial cells (Lee et al, 2007) . VEGF family members play a decisive role in formation of new blood vessels, such as induction of gene expression, regulation of vascular permeability, and promotion of cell migration, proliferation, and survival (Hoeben et al, 2004) . These are all induced by the binding of VEGF to VEGF-Rs, and the resulting activation of multiple downstream signaling pathways, including Ras/MAPK, FAK/paxillin, PI3K/AKT, and RhoA/ROCK PLCγ (Zachary, 2003 , Lee et al, 2007 and Johnson and wilgus, 2014 (Figure 1 ). The VEGF family consists of several proangiogenic proteins like VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor 1 and 2 (PIGF-1 and PIGF-2) (Gilbert, 2000 and Adair et al, 2010) . VEGF-A is known as most potent inducer of blood vessel growth, while VEGF-E is more specific for the pathological process of angiogenesis. Over expression of either VEGF-C or VEGF-D in tumors has been shown to significantly increase tumor-associated lymphatic vessel growth (primarily at the tumor margin) and increase the incidence of lymph node metastasis (lymphangiogenesis) (Feng et al, 2010) . Neuropilin-1 (NRP1) is a membrane-bound co-receptor for both VEGF and Semaphorin family members. NRP1 plays a versatile role in angiogenesis, axon guidance, cell survival, migration, and invasion (Li et al, 2014) . Neuropilin-2 (NRP2) is a receptor for vascular endothelial growth factor-C (VEGF-C), and a lymphangiogenic factor, which plays a major role in lymph node metastasis of various cancers, including breast cancer (Yasuoka et al, 2009 ). ANGPTL3 is a member of angiopoietin-like family of secreted factors, which consists of a signal peptide, N-terminal coiled-coil domain and the C-terminal fibrinogen (FBN)-like domain (Camenisch et al, 2002) . The FBN-like domain in angiopoietin-like3 protein was shown to bind -5/β-3 integrins, which induces endothelial cell adhesion and migration and also play a role in the regulation of angiogenesis as observed for VEGF-A (Camenisch et al, 2002) . The isoforms of platelet-derived growth factor (PDGF) (PDGFα and PDGFβ) will bind to the class III receptor tyrosine kinases, leading to the autophosphorylation of receptors at tyrosine residues and inducing the downstream signaling and it upregulates VEGF-A production to increase the angiogenic mechanisms (Laschke et al, 2006; Magnusson PU et al, 2007) . Lymph endothelial cells express Prox1, which was shown previously to induce lymphangiogenesis by activating VEGFR3 (Srinivasan et al, 2010) and may function as an oncogene or a tumor suppressor gene in a cancer-specific manner. Another protein SerpinF1 (SERPINF1) or pigment epithelium-derived factor (PEDF) has a multi-functional properties (anti tumorigenic and anti angiogensis). PEDF interferes with VEGF signaling through gamma-secretase activity, leading to the cleavage of VEGF receptor 1 (VEGFR-1) transmembrane domain, thereby inhibiting angiogenesis and endothelial cell migration (Cai et al, 2006) . Targeting these proteins might ameliorate the angiogenic/ lymphangiogenic capacity and thus can be exploited for the treatment for breast and other cancers. Role of VEGF signaling mechanism on angiogenesis and lymphangiogenesis. (adopted from RiniBl et al, 2007) Figure 1. Role of VEGF signaling mechanism on angiogenesis and lymphangiogenesis Current therapeutic interventions in breast cancer (BC) involves a multimodal approach (chemotherapy, radiation, surgery) based on the clinical heterogeneity. Several angiogenic inhibitors, which are various stages of clinical development, are found to be blocking the neoangiogenesis by depleting nutrients and oxygen to the tumor (Clarke et al, 2006) . Till date several drugs have been developed for treatment of cancers such as Bevacizumab, and multikinase inhibitors like Sorafenib, Sunitinib and Pazopanibetc (Dey et al, 2015) . Inspite of advances made in the diagnosis and treatment modalities, around 20-40% patients exhibit primary resistance to medical treatment (chemotherapy, hormone therapy, radiotherapy) (Varna et al, 2011) leading to morbidity and mortality. Death rate was found to be higher with cancer because of severe side effects of chemotherapy and radiation therapy.
In recent times, alternate and integrated approach to synergize drugs with neutraceuticals has opened up as a new strategy for better management of cancer. Most noted being naturally available food components like ginger, curcumin, allium vegetables including garlic, which contain the natural anti-Oxidant, anti-inflammatory, anti-cancerous properties (Mashhadi et al, 2013) , probably owing to their potent scavenging and apoptotic functions (Nigam et al, 2009 ). 6-Gingerol and 6-Shogaol are renowned food components isolated from Ginger (ZingiberofficinaleRosc) and well-documented for their contribution to human health and nutrition (Gupta and Sharma, 2014) . Indeed the use of Ginger as traditional medicine since immemorial decades as a curative for several diseases, including cancer, diabetes, bronchitis and arthritis… etc (Mashhadi et al, 2013) . Several evidences had suggested that Ginger and its active constituents suppress the tumor cell growth, induces apoptosis in a variety of cancers (Radhakrishnan et al, 2014) , inhibits vascular endothelial growth factor (VEGF), leads to the cell cycle arrest at G1 phase (Kim et al, 2005) and reduces the inflammatory molecules like Cyclooxgenease (COX2) (Saptarini et al, 2013) . In the present manuscript, we hypothesize that Ginger/ its derivatives (6-Gingerol and 6-Shogaol) function as promising nutraceuticals to block both angiogenesis and lymphangiogenesis and metastatic progression.
In the present study we aimed to study how nutraceuticals (Ginger derivatives (6-Gingerol and 6-Shogaol) will arrest the both angiogenesis and lymphangiogenesis progression using molecular docking studies.
Methodology
In the present study, we aimed to study the molecular docking interactions between ginger compounds (6-Gingerol and 6-Shogaol) (Figure 2a and 2b) and proteins [VEGF-A (3QTK), VEGF-C(2XIX), VEGFR-1 (5ABD), VEGFR-2/VEGF-E COMPLEX (3V6B), VEGF-C in complex with domains of 2 and 3 of VEGFR2 (2X1W), Nrp2 (4QDS), Neuropilin-1/VEGF-A complex (4DEQ), Angiopoietin-1 (4JYO), Angiopoietin-2 (4JZC), PDGF-B (4QCI), SERPINF1(5HGC), KDR (5EW3) and SOX18-HMG/PROX1-DNA (4Y60)], which plays crucial role in angiogenesis and lymph angiogenesis. Molecular docking is used to screening of 6-Gingerol and 6-Shogaol for potential cancer target genes were shown in Figure 3a and 3b and site of interactions were listed in Table 1 . 
Molecular Docking Target Preparation
The target proteins associated with angiogenesis and lymphangiogenesis were downloaded from Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do) and are listed in (Table 1) . For crystal structure of each target, the crystallographic water molecules were removed, the missing hydrogen atoms were added and the energy level of all the targets was minimized using Accelrys Discovery Studio (Dassault Systè mes BIOVIA, BIOVIA Workbook, Release 2017; BIOVIA Pipeline Pilot, Release 2017, San Diego: Dassault Systè mes).The complex protein-ligand docking interactions were performed by Accelrys Discovery Studio (version 2.5) which was used to design the molecules, and protein binding affinities, and number of bonds formed by ligand (6-Gingerol and 6-Shogaol) with the target protein.
The molecular docking was performed between the ginger compounds (6-Gingerol and 6-Shogaol) (Figure 2a and 2b ) and the protein molecules which are involved in angiogenesis and lymphangiogenesis using Ligfit. Ligfit is a high-throughput algorithm for docking ligands into an active binding site on the receptor, which is also a site-features docking algorithm. Accelrys CHARMm force field was used throughout the simulation before running Ligfit. The bond distance between ligand residues and protein receptor i.e. <3.10A o consider to be significant, which has stronger interactions and binding affinity to be high. >3.10 A o was ignored from the docking studies (Table 1) .
Results and Discussion
Angiogenesis helps in the supply of nutrients and oxygen through neovascularization of lymph and blood vessels for the tumor establishment and growth (Paduch, 2016) . Recent studies had demonstrated that lymphangiogenesis also contributes to the development of metastasis (Christiansen and Detmar, 2011) . Vascular endothelial growth factors (VEGF family) are proangiogenic, and plays significant role in angiogenesis and lymphangiogenesis. Several studies had demonstrated that the phenolic compounds of ginger i.e. 6-Gingerol and 6-Shogaol are hydrophobic due to their aromatic ring and methoxy group, and possesses apoptotic, anti inflammatory, anti-metastatic properties. The ligands of ginger compounds (6-Gingerol and 6-Shogaol) have OH groups on their benzyl ring, which mostly interacts with NH group of selected protein targets such as VEGF-A (3QTK), VEGF-C(2XIX), VEGFR-1 (5ABD), VEGFR-2/VEGF-E COMPLEX (3V6B), VEGF-C in complex with domains of 2 and 3 of VEGFR2 (2X1W), Nrp2 (4QDS), Neuropilin-1/VEGF-A complex (4DEQ), Angiopoietin-2 (4JZC), PDGF-B (4QCI), SERPINF1(5HGC), KDR (5EW3) and SOX18-HMG/PROX1-DNA (4Y60) demonstrating less distance between receptor and ligand cavity(A O ), and with higher binding affinity, in addition to hydrogen bond interactions or Vander waals force being more in these groups.
Oxygen ( (Table 1 ) (Figure 3a and 3b ). This advocate that 6-Gingerol inhibits the VEGF family members alters vascularization. In vitro and in vivo studies have also confirmed the role of 6-Gingerol to inhibit VEGF, reduce angiogenesis (Kim et al, 2005) , whereas oxygen (O) residue of 6-Shogaol also interacts with receptor sites of VEGF-A (3QTK) -[ARG75-NH2 (2.73)], VEGF-C (2XIX)-[ ASN175-ND2(3.10)], VEGFR1 (5ABD)-[THR166-NH (2.84)], VEGFR-2/VEGF-E complex(3V6B)-[ARG46-NH1(2.71) and GLY196-NH (2.79)], VEGF-C in complex with domains 2 and 3 of VEGFR2(2X1W) -[ASN175-ND2 (2.59)] (Table 1) indicating that 6-Shogaol association is significant with VEGF family members and its impact on anti-angiogenic potential. Moreover, oxygen (O) ligand residue of 6-Gingerol is more likely to interact with Nrp2 protein at different receptor sites at ARG421-NE (1.27), ARG421-NH1 (1.66), ARG421-NH (2.12), ARG421-NH (2.89) and GLY313-NH (2.15) and 6-Shogaol with oxygen (O) ligand residue also interacts with NRP2 at receptor site ARG421-NH (2.13), ARG421-NH2 (2.48), ARG421-NH1 (2.63) and GLY313-NH (2.70) with less bond distance and more binding affinity and stronger vander waal interactions. Similarly 6-Gingerol and 6-Shogaol have shown to interact with different receptor sites/ amino acid residues of Neuropilin-1/VEGF-A complex (4DEQ), Angiopoietin-1 (4JYO), Angiopoietin-2 (4JZC), PDGF-B (4QCI), SERPINF1 (5HGC), KDR (5EW3), Type IX collagen NC2 (5CTD) and SOX18-HMG/PROX1-DNA (4Y60) to suggest that 6-Gingerol and 6-Shoagaol had anti angiogenic and anti-mechanistic properties. These hydrophobic interactions might change the angiogenic/lymphangiogenic potential of these selected proteins. Among these selected compounds, the 6-Gingerol is more potent inhibitor of lymphangiogenesis which is more specific to binding with VEGF-C and NRP2.
Conclusions
The present study using in silico approach, suggest beneficial role of ginger compounds (6-Gingerol and 6-Shogaol) as growth inhibitors and modulators of lymphangiogenesis, angiogenesis molecules (VEGF-A, VEGF-C, Nrp2, Agiopoietin-2, PDGF-B, SERPINF1, KDR.etc) which is involved in metastatic progression of breast cancer. Intervention with 6-Gingerol and 6-Shogaol, which prove to be cost effective and without side effects might be helpful in management of breast cancer patients as well as in related epithelial-mediated cancers. The in silico approach might be useful for therapeutic intervention of novel drugs and control of angiogenesis (lymphangiogenesis) after clinical trials on cancer patients. Further, validation of these insilico results will be carried out by in vitro and in vivo studies.
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